In the US, Adalimumab (adalimumab systemic) is a member of the following drug classes: antirheumatics, TNF alfa inhibitors and is used to treat Ankylosing Spondylitis, Behcet's Disease, Crohn's Disease, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Reiter's Syndrome, Rheumatoid Arthritis, Sarcoidosis, Spondyloarthritis and Ulcerative Colitis.
- Adalimumab Prefilled Pens and Syringes
- Adalimumab Vials
- Adalimumab Subcutaneous
- Adalimumab-adbm Subcutaneous
- Adalimumab-atto Subcutaneous
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Disease-modifying antirheumatic drug, DMARD
Tumor necrosis factor alpha (TNF-α) inhibitor
Immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7κ-chain, dimer (WHO )
- Adalimumabum (Latin)
- Adalimumab (German)
- Adalimumab (French)
- Adalimumab (Spanish)
- Adalimumab (OS: BAN, USAN)
- Adalimumab (Genetical Recombination) (OS: JAN)
- D 2E7 (IS)
- LU 200134 (IS)
Abbott, Argentina; Abbott, China; Abbott, Czech Republic; Abbott, Ecuador; Abbott, Egypt; Abbott, Italy; Abbott, Oman; Abbott, Peru; Abbott, Romania; Abbott, Serbia; Abbott, Russian Federation; Abbott, Slovakia; Abbott, Tunisia; Abbott, Taiwan; Abbott, Venezuela; Abbott, South Africa; Abbott Laboratories, Lithuania; Abbott Laboratories de Chile, Chile; AbbVie, Austria; AbbVie, Australia; AbbVie, Belgium; AbbVie, Canada; AbbVie, Switzerland; AbbVie, Germany; AbbVie, Denmark; AbbVie, France; AbbVie, United Kingdom; AbbVie, Greece; AbbVie, Hong Kong; AbbVie, Croatia (Hrvatska); AbbVie, Hungary; AbbVie, Ireland; AbbVie, Japan; AbbVie, South Korea; AbbVie, Latvia; AbbVie, Netherlands; AbbVie, Norway; AbbVie, New Zealand; AbbVie, Sweden; AbbVie, Singapore; AbbVie, Turkey; AbbVie, United States; AbbVie A/S, Iceland; ABBVIE BIOPHARMACEUTICALS, Israel; Abbvie Farmacéuticos, Mexico; AbbVie Inc., Bosnia & Herzegowina; AbbVie Polska, Poland; Vetter Pharma, Lebanon
- Humira (pediatric)
AbbVie, United Kingdom
- Humira Kinder (pediatric)
- Humira Pediatrico (pediatric)
- Humira Pédiatrique (pediatric)
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.